Yahoo
ASX - Delayed Quote AUD

AFT Pharmaceuticals Limited (AFP.AX)

3.6800 +0.0600 (+1.66%)
At close: November 3 at 10:45:32 AM GMT+11
Chart Range Bar
Loading chart for AFP.AX
  • Previous Close 3.6200
  • Open 3.6800
  • Bid 3.6000 x --
  • Ask 3.6900 x --
  • Day's Range 3.6800 - 3.6800
  • 52 Week Range 2.7000 - 4.1300
  • Volume 259
  • Avg. Volume 1,309
  • Market Cap (intraday) 385.939M
  • Beta (5Y Monthly) 0.52
  • PE Ratio (TTM) 28.31
  • EPS (TTM) 0.1300
  • Earnings Date --
  • Forward Dividend & Yield 0.01 (0.37%)
  • Ex-Dividend Date Jun 18, 2026
  • 1y Target Est --

AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers proprietary and in-licensed products, including patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, natural health, pain management, skin care, sleeping aids, supplements, and other products. It has a research and development collaboration with Hyloris Pharmaceuticals SA for the development of the Maxigesic IV product. AFT Pharmaceuticals Limited was incorporated in 1997 and is headquartered in Auckland, New Zealand.

www.aftpharm.com

126

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/3/2026, which may include dividends or other distributions. Benchmark is S&P/NZX 50 INDEX GROSS ( GROSS (^NZ50) .

YTD Return

AFP.AX
23.21%
S&P/NZX 50 INDEX GROSS ( GROSS (^NZ50)
1.27%

1-Year Return

AFP.AX
30.15%
S&P/NZX 50 INDEX GROSS ( GROSS (^NZ50)
1.11%

3-Year Return

AFP.AX
16.45%
S&P/NZX 50 INDEX GROSS ( GROSS (^NZ50)
23.40%

5-Year Return

AFP.AX
11.10%
S&P/NZX 50 INDEX GROSS ( GROSS (^NZ50)
6.00%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    5.78%

  • Return on Assets (ttm)

    7.90%

  • Return on Equity (ttm)

    13.66%

  • Revenue (ttm)

    254.7M

  • Net Income Avi to Common (ttm)

    14.73M

  • Diluted EPS (ttm)

    0.1300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    10.24M

  • Total Debt/Equity (mrq)

    49.61%

  • Levered Free Cash Flow (ttm)

    -20.96M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: